US 2002/0177604 A1Published application

4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents

AssigneePharmacia & Upjohn Company

InventorsValerie A. Vaillancourt, Atli Thorarensen

Life of this patent

Estimating the term…

Abstract

The present invention provides a compound of Formula III 1 which is useful for the treatment or prevention of herpes viruses.

Claims31

Dependent claims

A compound of formula III:

26
or a pharmaceutically acceptable salt thereof wherein,
A is
(a) Cl,
(b) Br,
(c) CN,
(d) NO2, or
(e) F;
R1 is
(a) R5,
(b) NR7R8, or
(c) SO2R9;
R2 is
(a) aryl,
(b) het,
(c) SOmR6,
(d) OC2-7 alkyl substituted by OH,
(e) SC2-7 alkyl substituted by OH, or
(f) C2-8 alkyl which is partially unsaturated and is optionally substituted by one or more substituents selected from R11, OR13, SR13, NR7R8, halo, (C═O)C1-7 alkyl or SOmR9;
with the proviso that when R1═R5═(CH2CH2O)iR10, then R2 may additionally represent
(a) H,
(b) halo,
(c) (C═O)R6,
(d) (C═O)OR9,
(e) cyano,
(f) OR10,
(g) Ohet,
(h) NR7R8,
(i) SR10,
(j) Shet,
(k) NHCOR12,
(l) NHSO2R12, or
(m) R2 together with R3 or R4 form a carbocyclic or het which may be optionally substituted by NR7R8, or C1-7alkyl which may be optionally substituted by OR14;
R3 and R4 are independently:
(a) H,
(b) halo,
(c) aryl,
(d) S(O)mR6,
(e) (C═O)R6,
(f) (C═O)OR9,
(g) cyano,
(h) het, wherein said het is bound via a carbon atom,
(i) OR10,
(j) Ohet,
(k) NR7R8,
(l) SR10,
(m) Shet,
(n) NHCOR12,
(o) NHSO2R12,
(p) C1-7alkyl which may be partially unsaturated and optionally substituted by one or more substituents of the group R11, OR13, SR10, SR13, NR7R8, halo, (C═O)C1-7alkyl, or SOmR9, or
(q) R4 together with R3 form a carbocyclic or het which may be optionally substituted by NR7R8, or C1-7alkyl which may be optionally substituted by OR14;
R5 is
(a) (CH2CH2O)iR10,
(b) het, wherein said bet is bound via a carbon atom,
(c) aryl,
(d) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR7R8, R11, SOmR9, or OC2-4alkyl which may be further substituted by het, OR10, or NR7R8, or
(e) C3-8cycloalkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from R11, NR7R8, SOmR9, or C1-7alkyl optionally substituted by R11, NR7R8, or SOmR9;
R6 is
(a) C1-7alkyl,
(b) NR7R8,
(c) aryl, or
(d) het, wherein said het is bound via a carbon atom;
R7 and R8 are independently
(a) H,
(b) aryl,
(c) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SOmR9, CONR10R10, or halo, or,
(d) R7 and R8 together with the nitrogen to which they are attached form a het;
R9 is
(a) aryl,
(b) bet,
(c) C3-8cycloalkyl,
(d) methyl, or
(e) C2-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SH, CONR10R10, or halo;
R10 is
(a) H,
(b) methyl, or
(c) C2-7alkyl optionally substituted by OH;
R11 is
(a) OR10,
(b) Ohet,
(c) Oaryl,
(d) CO2R10,
(e) het,
(f) aryl, or
(g) CN;
R12 is
(a) H,
(b) het,
(c) aryl,
(d) C3-8cycloalkyl,
(e) methyl, or
(f) C2-7alkyl optionally substituted by NR7R8 or R11;
R13 is
(a) (P═O)(OR14)2,
(b) CO(CH2)nCON(CH3)—(CH2)nSO3−M+,
(c) an amino acid,
(d) C(═O)aryl, or
(e) C(═O)C1-7alkyl optionally substituted by NR7R8, aryl, het, CO2H, or O(CH2)nCO2R14;
R14 is
(a) H, or
(b) C1-7alkyl;
each i is independently 2, 3, or 4;
each n is independently 1, 2, 3, 4 or 5;
each m is independently 0, 1, or 2;
M is sodium, potassium, or lithium;
aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;
wherein any aryl is optionally substituted with one or more substituents selected from halo, OH, cyano, CO2R14, CF3, C1-6alkoxy, and C1-6 alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups;
het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;
wherein any het is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, CO2R14, CF3, C1-6alkoxy, oxo, oxime, and C1-6 alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups.

106 more elements

A composition of matter comprising a pharmaceutically effective amount of a compound of formula (III):

27
or a pharmaceutically acceptable salt thereof wherein,
A is
(a) Cl,
(b) Br,
(c) CN,
(d) NO2, or
(e) F;
R1 is
(a) R5,
(b) NR7R8, or
(c) SO2R9;
R2 is
(a) aryl,
(b) het,
(c) SOmR6,
(d) OC2-7 alkyl substituted by OH,
(e) SC2-7 alkyl substituted by OH, or
(f) C2-8 alkyl which is partially unsaturated and is optionally substituted by one or more substituents selected from R11, OR13, SR13, NR7R8, halo, (C═O)C1-7 alkyl or SOmR9;
with the proviso that when R1═R5═(CH2CH2O)iR10, then R2 may additionally represent
(a) H,
(b) halo,
(c) (C═O)R6,
(d) (C═O)OR9,
(e) cyano,
(f) OR10,
(g) Ohet,
(h) NR7R8,
(i) SR10,
(j) Shet,
(k) NHCOR12,
(l) NHSO2R12;
or
(m) R2 together with R3 or R4 form a carbocyclic or het which may be optionally substituted by NR7R8, or C1-7alkyl which may be optionally substituted by OR14;
R3 and R4 are independently:
(a) H,
(b) halo,
(c) aryl,
(d) S(O)mR6,
(e) (C═O)R6,
(f) (C═O)OR9,
(g) cyano,
(h) het, wherein said het is bound via a carbon atom,
(i) OR10,
() Ohet,
(k) NR7R8,
(l) SR10,
(m) Shet,
(n) NHCOR12,
(o) NHSO2R12,
(p) C1-7alkyl which may be partially unsaturated and optionally substituted by one or more substituents of the group R11, OR13, SR10, SR13, NR7R8, halo, (C═O)C1-7alkyl, or SOmR9, or
(q) R4 together with R3 form a carbocyclic or het which may be optionally substituted by NR7R8, or C1-7alkyl which may be optionally substituted by OR14;
R5 is
(a) (CH2CH2O)iR10,
(b) het, wherein said het is bound via a carbon atom,
(c) aryl,
(d) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR7R8, R11, SOmR9, or OC2-4alkyl which may be further substituted by het, OR10, or NR7R8, or
(e) C3-8cycloalkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from R11, NR7R8, SOmR9, or C1-7alkyl optionally substituted by R11, NR7R8, or SOmR9;
R6 is
(a) C1-7alkyl,
(b) NR7R9,
(c) aryl, or
(d) het, wherein said het is bound via a carbon atom;
R7 and R8 are independently
(a) H,
(b) aryl,
(c) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SOmR9, CONR10R10, or halo, or,
(d) R7 and R8 together with the nitrogen to which they are attached form a het;
R9 is
(a) aryl,
(b) het,
(c) C3-8Cycloalkyl,
(d) methyl, or
(e) C2-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SH, CONR10R10, or halo;
R10 is
(a) H,
(b) methyl, or
(c) C2-7alkyl optionally substituted by OH;
R11 is
(a) OR10,
(b) Ohet,
(c) Oaryl,
(d) CO2R10,
(e) het,
(f) aryl, or
(g) CN;
R12 is
(a) H,
(b) het,
(c) aryl,
(d) C3-8cycloalkyl,
(e) methyl, or
(f) C2-7alkyl optionally substituted by NR7R8 or R11;
R13 is
(a) (P═O)(OR14)2,
(b) CO(CH2)nCON(CH3)—(CH2)nSO3−M+,
(c) an anino acid,
(d) C(═O)aryl, or
(e) C(═O)C1-7alkyl optionally substituted by NR7R8, aryl, het, CO2H, or O(CH2)nCO2R14;
R14 is
(a) H, or
(b) C1-7alkyl;
each i is independently 2, 3, or 4;
each n is independently 1, 2, 3, 4 or 5;
each m is independently 0, 1, or 2;
M is sodium, potassium, or lithium;
aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;
wherein any aryl is optionally substituted with one or more substituents selected from halo, OH, cyano, CO2R14, CF3, C1-6alkoxy, and C1-6alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups;
het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;
wherein any het is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, CO2R14, CF3, C1-6alkoxy, oxo, oxime, and C1-6 alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups;
and a pharmaceutically effective carrier.

108 more elements

A method for treating a disease or condition in a mammal caused by a viral infection, comprising administering to the mammal a therapeutically effective amount of a compound of formula (IIIa)

28
or a pharmaceutically acceptable salt thereof wherein,
A is
(a) Cl,
(b) Br,
(c) CN,
(d) NO2, or
(e) F;
R1 is
(a) R5,
(b) NR7R8, or
(c) SO2R9;
R2, R3 and R4 are independently:
(a) H,
(b) halo,
(c) aryl,
(d) S(O)mR6,
(e) (C═O)R6,
(f) (C═O)OR9,
(g) cyano,
(h) het, wherein said het is bound via a carbon atom,
(i) OR10,
(j) Ohet,
(k) NR7R8,
(l) SR10,
(m) Shet,
(n) NHCOR12,
(o) NHSO2R12,
(p) C1-7alkyl which may be partially unsaturated and optionally substituted by one or more substituents of the group R11, OR13, SR10, SR13, NR7R8, halo, (C═O)C1-7alkyl, or SOmR9, or
(q) R4 together with R3 form a carbocyclic or het which may be optionally substituted by NR7R8, or C1-7alkyl which may be optionally substituted by OR14;
R5 is
(a) (CH2CH2O)iR10,
(b) het, wherein said het is bound via a carbon atom,
(c) aryl,
(d) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR7R8, R11, SOmR9, or OC2-4alkyl which may be further substituted by het, OR10 or NR7R8, or
(e) C3-8cycloalkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from R11, NR7R8, SOmR9, or C1-7alkyl optionally substituted by R11, NR7R8, or SOmR9;
R6 is
(a) C1-7alkyl,
(b) NR7R8,
(c) aryl, or
(d) het, wherein said het is bound via a carbon atom;
R7 and R8 are independently
(a) H,
(b) aryl,
(c) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SOmR9, CONR10R10, or halo, or,
(d) R7 and R8 together with the nitrogen to which they are attached form a het;
R9 is
(a) aryl,
(b) het,
(c) C3-8cycloalkyl,
(d) methyl, or
(e) C2-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SH, CONR10R10,or halo;
R10 is
(a) H,
(b) methyl, or
(c) C2-7alkyl optionally substituted by OH;
R11 is
(a) OR10,
(b) Ohet,
(c) Oaryl,
(d) CO2R10,
(e) het,
(f) aryl, or
(g) CN;
R12 is
(a) H,
(b) het,
(c) aryl,
(d) C3-8cycloalkyl,
(e) methyl, or
(f) C2-7alkyl optionally substituted by NR7R8 or R11;
R13 is
(a) (P═O)(OR14)2,
(b) CO(CH2)nCON(CH3)—(CH2)nSO3−M+,
(c) an amino acid,
(d) C(═O)aryl, or
(e) C(═O)C1-7alkyl optionally substituted by NR7R8, aryl, het, CO2H, or O(CH2)nCO2R14;
R14 is
(a) H, or
(b) C1-7alkyl;
each i is independently 2, 3, or 4;
each n is independently 1, 2, 3, 4 or 5;
each m is independently 0, 1, or 2;
M is sodium, potassium, or lithium;
aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;
wherein any aryl is optionally substituted with one or more substituents selected from halo, OH, cyano, CO2R14, CF3, C1-6alkoxy, and C1-6 alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups;
het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;
wherein any het is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, CO2R14, CF3, C1-6alkoxy, oxo, oxime, and C1-6alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups.

85 more elements

A method for inhibiting a viral DNA polymerase, comprising contacting the polymerase with an effective inhibitory amount of formula (IIIa)

29
or a pharmaceutically acceptable salt thereof wherein,
A is
(a) Cl,
(b) Br,
(c) CN,
(d) NO2, or
(e) F;
R1 is
(a) R5,
(b) NR7R8, or
(c) SO2R9;
R2, R3 and R4 are independently:
(a) H,
(b) halo,
(c) aryl,
(d) S(O)mR6,
(e) (C═O)R6,
(f) (C═O)OR9,
(g) cyano,
(h) het, wherein said het is bound via a carbon atom,
(i) OR10,
(j) Ohet,
(k) NR7R8,
(l) SR10,
(m) Shet,
(n) NHCOR12,
(o) NHSO2R12,
(p) C1-7alkyl which may be partially unsaturated and optionally substituted by one or more substituents of the group R11, OR13, SR10, SR13, NR7R8, halo, (C═O)C1-7alkyl, or SOmR9, or
(q) R4 together with R3 form a carbocyclic or het which may be optionally substituted by NR7R8, or C1-7alkyl which may be optionally substituted by OR14;
R5 is
(a) (CH2CH2O)iR10,
(b) het, wherein said het is bound via a carbon atom,
(c) aryl,
(d) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR7R8, R11, SOmR9, or OC2-4alkyl which may be further substituted by het, OR10, or NR7R8, or
(e) C3-8cycloalkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from R11, NR7R8, SOmR9, or C1-7alkyl optionally substituted by R11, NR7R8, or SOmR9;
R6 is
(a) C1-7alkyl,
(b) NR7R8,
(c) aryl, or
(d) het, wherein said het is bound via a carbon atom;
R7 and R8 are independently
(a) H,
(b) aryl,
(c) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SOmR9, CONR10R10, or halo, or,
(d) R7 and R8 together with the nitrogen to which they are attached form a het;
R9 is
(a) aryl,
(b) het,
(c) C3-8cycloalkyl,
(d) methyl, or
(e) C2-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SH, CONR10R10, or halo;
R10 is
(a) H,
(b) methyl, or
(c) C2-7alkyl optionally substituted by OH;
R11 is
(a) OR10,
(b) Ohet,
(c) Oaryl,
(d) CO2R10,
(e) het,
(f) aryl, or
(g) CN;
R12 is
(a) H,
(b) het,
(c) aryl,
(d) C3-8cycloalkyl,
(e) methyl, or
(f) C2-7alkyl optionally substituted by NR7R8 or R11;
R13 is
(a) (P═O)(OR14)2,
(b) CO(CH2)nCON(CH3)—(CH2)nSO3−M+,
(c) an amino acid,
(d) C(═O)aryl, or
(e) C(═O)C1-7alkyl optionally substituted by NR7R8, aryl, het, CO2H, or O(CH2)nCO2R14;
R14 is
(a) H, or
(b) C1-7alkyl;
each i is independently 2, 3, or 4;
each n is independently 1, 2, 3, 4 or 5;
each m is independently 0, 1, or 2;
M is sodium, potassium, or lithium;
aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;
wherein any aryl is optionally substituted with one or more substituents selected from halo, OH, cyano, CO2R14, CF3, C1-6alkoxy, and C1-6 alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups;
het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;
wherein any het is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, CO2R14, CF3, C1-6alkoxy, oxo, oxime, and C1-6 alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups.
or a pharmaceutically acceptable salt thereof.

86 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/151,439Filed 20 May 2002
Priority: 21 Mar 2000
Published: 28 Nov 2002
Term ends: Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61P 31/22
For DNA viruses: for herpes viruses
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00
C07D
Heterocyclic compounds

Family

Application60/190,979Us provisional application · filed 21 Mar 2000
Application09/808,757Division · filed 15 Mar 2001
Application10/151,439Division · filed 20 May 2002
US 2002/0019413 A1Published application
US 6,451,811 B2Related patent
US 6,693,114 B2Related patent
US 2002/0177604 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

A compound of formula III:

26
or a pharmaceutically acceptable salt thereof wherein,
A is
(a) Cl,
(b) Br,
(c) CN,
(d) NO2, or
(e) F;
R1 is
(a) R5,
(b) NR7R8, or
(c) SO2R9;
R2 is
(a) aryl,
(b) het,
(c) SOmR6,
(d) OC2-7 alkyl substituted by OH,
(e) SC2-7 alkyl substituted by OH, or
(f) C2-8 alkyl which is partially unsaturated and is optionally substituted by one or more substituents selected from R11, OR13, SR13, NR7R8, halo, (C═O)C1-7 alkyl or SOmR9;
with the proviso that when R1═R5═(CH2CH2O)iR10, then R2 may additionally represent
(a) H,
(b) halo,
(c) (C═O)R6,
(d) (C═O)OR9,
(e) cyano,
(f) OR10,
(g) Ohet,
(h) NR7R8,
(i) SR10,
(j) Shet,
(k) NHCOR12,
(l) NHSO2R12, or
(m) R2 together with R3 or R4 form a carbocyclic or het which may be optionally substituted by NR7R8, or C1-7alkyl which may be optionally substituted by OR14;
R3 and R4 are independently:
(a) H,
(b) halo,
(c) aryl,
(d) S(O)mR6,
(e) (C═O)R6,
(f) (C═O)OR9,
(g) cyano,
(h) het, wherein said het is bound via a carbon atom,
(i) OR10,
(j) Ohet,
(k) NR7R8,
(l) SR10,
(m) Shet,
(n) NHCOR12,
(o) NHSO2R12,
(p) C1-7alkyl which may be partially unsaturated and optionally substituted by one or more substituents of the group R11, OR13, SR10, SR13, NR7R8, halo, (C═O)C1-7alkyl, or SOmR9, or
(q) R4 together with R3 form a carbocyclic or het which may be optionally substituted by NR7R8, or C1-7alkyl which may be optionally substituted by OR14;
R5 is
(a) (CH2CH2O)iR10,
(b) het, wherein said bet is bound via a carbon atom,
(c) aryl,
(d) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR7R8, R11, SOmR9, or OC2-4alkyl which may be further substituted by het, OR10, or NR7R8, or
(e) C3-8cycloalkyl which may be partially unsaturated and optionally substituted by one or more substituents selected from R11, NR7R8, SOmR9, or C1-7alkyl optionally substituted by R11, NR7R8, or SOmR9;
R6 is
(a) C1-7alkyl,
(b) NR7R8,
(c) aryl, or
(d) het, wherein said het is bound via a carbon atom;
R7 and R8 are independently
(a) H,
(b) aryl,
(c) C1-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SOmR9, CONR10R10, or halo, or,
(d) R7 and R8 together with the nitrogen to which they are attached form a het;
R9 is
(a) aryl,
(b) bet,
(c) C3-8cycloalkyl,
(d) methyl, or
(e) C2-7alkyl which may be partially unsaturated and is optionally substituted by one or more substituents selected from NR10R10, R11, SH, CONR10R10, or halo;
R10 is
(a) H,
(b) methyl, or
(c) C2-7alkyl optionally substituted by OH;
R11 is
(a) OR10,
(b) Ohet,
(c) Oaryl,
(d) CO2R10,
(e) het,
(f) aryl, or
(g) CN;
R12 is
(a) H,
(b) het,
(c) aryl,
(d) C3-8cycloalkyl,
(e) methyl, or
(f) C2-7alkyl optionally substituted by NR7R8 or R11;
R13 is
(a) (P═O)(OR14)2,
(b) CO(CH2)nCON(CH3)—(CH2)nSO3−M+,
(c) an amino acid,
(d) C(═O)aryl, or
(e) C(═O)C1-7alkyl optionally substituted by NR7R8, aryl, het, CO2H, or O(CH2)nCO2R14;
R14 is
(a) H, or
(b) C1-7alkyl;
each i is independently 2, 3, or 4;
each n is independently 1, 2, 3, 4 or 5;
each m is independently 0, 1, or 2;
M is sodium, potassium, or lithium;
aryl is a phenyl radical or an ortho-fused bicyclic carbocyclic radical wherein at least one ring is aromatic;
wherein any aryl is optionally substituted with one or more substituents selected from halo, OH, cyano, CO2R14, CF3, C1-6alkoxy, and C1-6 alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups;
het is a four- (4), five- (5), six- (6), or seven- (7) membered saturated or unsaturated heterocyclic ring having 1, 2, or 3 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, which is optionally fused to a benzene ring, or any bicyclic heterocycle group;
wherein any het is optionally substituted with one or more substituents selected from the group consisting of halo, OH, cyano, phenyl, CO2R14, CF3, C1-6alkoxy, oxo, oxime, and C1-6 alkyl which may be further substituted by one to three SR14, NR14R14, OR14, or CO2R14 groups.

106 more elements

Facts

Application

10/151,439Filed 20 May 2002

Priority

21 Mar 2000

Published

28 Nov 2002

Term ends

Not estimatedThe source records don’t support an estimate.

Classification5 codes

C07D 471/04
In which the condensed system contains two hetero rings: ortho-condensed systems
A61P 31/22
For DNA viruses: for herpes viruses
A61P 43/00
Drugs for specific purposes, not provided for in groups a61p1/00-a61p41/00
C07D
Heterocyclic compounds

Family

Application60/190,979Us provisional application · filed 21 Mar 2000

Application09/808,757Division · filed 15 Mar 2001

Application10/151,439Division · filed 20 May 2002

US 2002/0019413 A1Published application

US 6,451,811 B2Related patent

US 6,693,114 B2Related patent

US 2002/0177604 A1This patent

From the US filing history. Foreign family members aren’t listed.